BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7834627)

  • 1. N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug.
    Moselen JW; Hay MP; Denny WA; Wilson WR
    Cancer Res; 1995 Feb; 55(3):574-80. PubMed ID: 7834627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers.
    Hay MP; Wilson WR; Moselen JW; Palmer BD; Denny WA
    J Med Chem; 1994 Feb; 37(3):381-91. PubMed ID: 8308864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
    Palmer BD; Wilson WR; Anderson RF; Boyd M; Denny WA
    J Med Chem; 1996 Jun; 39(13):2518-28. PubMed ID: 8691449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
    Lee HH; Wilson WR; Denny WA
    Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
    Fracasso PM; Sartorelli AC
    Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
    Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA
    J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore.
    Papadopoulou MV; Bloomer WD
    Anticancer Drugs; 2009 Jul; 20(6):493-502. PubMed ID: 19430289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins.
    Hay MP; Denny WA; Wilson WR
    Anticancer Drug Des; 1996 Jul; 11(5):383-402. PubMed ID: 8765531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions.
    Hughes CS; Irvin CG; Rockwell S
    Cancer Commun; 1991 Feb; 3(2):29-35. PubMed ID: 1899798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
    Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
    Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerobic and hypoxic toxicity of a new class of mixed-function drugs associating nitroimidazoles and chloroethylnitrosourea in nitrosourea-sensitive (Mer-) and -resistant (Mer+) human tumor cells.
    Mulcahy RT; Carminati A; Barascut JL; Imbach JL
    Cancer Res; 1988 Feb; 48(4):798-801. PubMed ID: 3338077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs.
    Siim BG; Atwell GJ; Anderson RF; Wardman P; Pullen SM; Wilson WR; Denny WA
    J Med Chem; 1997 Apr; 40(9):1381-90. PubMed ID: 9135035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
    Papadopoulou MV; Bloomer WD
    In Vivo; 2007; 21(2):175-80. PubMed ID: 17436565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NLNQ-1, a 2-[3-(2-nitro-1-imidazolyl) propylamino]-3-chloro-1,4-naphthoquinone, as a hypoxia-selective cytotoxin and radiosensitizer.
    Papadopoulou MV; Bloomer WD
    In Vivo; 2008; 22(3):285-8. PubMed ID: 18610737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.
    Fourie J; Guziec F; Guziec L; Monterrosa C; Fiterman DJ; Begleiter A
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):191-203. PubMed ID: 14614574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility.
    Hay MP; Lee HH; Wilson WR; Roberts PB; Denny WA
    J Med Chem; 1995 May; 38(11):1928-41. PubMed ID: 7783125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
    Papadopoulou MV; Rosenzweig HS; Bloomer WD
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1523-5. PubMed ID: 15006395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild-type and repair-deficient cell lines.
    Kim SY; Rockwell S
    Oncol Res; 1995; 7(5):39-47. PubMed ID: 8534933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild-type and repair-deficient cell lines.
    Rockwell S; Kim SY
    Oncol Res; 1995; 7(1):39-47. PubMed ID: 7549043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.